BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 6421755)

  • 21. Use of 'single donor' factor VIII from plasma exchange donation.
    McLeod BC; Scott JP
    JAMA; 1984 Nov; 252(19):2726-9. PubMed ID: 6436520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blood products.
    Med Lett Drugs Ther; 1979 Nov; 21(23):93-6. PubMed ID: 502967
    [No Abstract]   [Full Text] [Related]  

  • 23. The use of chromatography to manufacture purer and safer plasma products.
    Johnston A; Adcock W
    Biotechnol Genet Eng Rev; 2000; 17():37-70. PubMed ID: 11255674
    [No Abstract]   [Full Text] [Related]  

  • 24. [Optimum use of human blood].
    van Aken WG; Brummelhuis HG; Prins HK; von dem Borne AE
    Ned Tijdschr Geneeskd; 1978 Sep; 122(37):1362-75. PubMed ID: 692763
    [No Abstract]   [Full Text] [Related]  

  • 25. Fractionation of plasma with polyethylene glycol.
    Polson A; Ruiz-Bravo C
    Vox Sang; 1972; 23(1):107-18. PubMed ID: 5081005
    [No Abstract]   [Full Text] [Related]  

  • 26. Factor VIII collection by pheresis.
    McLeod BC; Sassetti RJ; Cole ER; Pierce MI
    Lancet; 1980 Sep; 2(8196):671-3. PubMed ID: 6106786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Self-sufficiency for plasma and plasma proteins in Norway.
    Solheim BG; Eggen BM; Heier HE
    Beitr Infusionsther Transfusionsmed; 1996; 33():98-102. PubMed ID: 8865939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of different intensities of regular donor plasmapheresis on humoral and cellular immunity, red cell and iron metabolism, and cardiovascular risk markers.
    Tran-Mi B; Storch H; Seidel K; Schulzki T; Haubelt H; Anders C; Nagel D; Siegler KE; Vogt A; Seiler D; Hellstern P
    Vox Sang; 2004 Apr; 86(3):189-97. PubMed ID: 15078254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The apheresis: plasmapheresis, plateletpheresis, leukapheresis. Physiopathology of the donor (author's transl)].
    Avanzi G
    Pathologica; 1978; 70(1007-1008):467-80. PubMed ID: 370755
    [No Abstract]   [Full Text] [Related]  

  • 30. Observation of the changes of plasma proteins after long term plasmapheresis.
    Grgicević D; Pistotnik M; Pende B
    Dev Biol Stand; 1980; 48():279-86. PubMed ID: 6168506
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Quarantine and plasmapheresis].
    Ortiz Pareja M; Terol Fernández E; Hernández Lamas MC; Sánchez Gordo F
    Sangre (Barc); 1998 Jun; 43(3):261-2. PubMed ID: 9741240
    [No Abstract]   [Full Text] [Related]  

  • 32. Management of plasmapheresis in France.
    Cazenave JP; Folléa G
    Hematol Cell Ther; 1996 May; 38 Suppl 1():S25-33. PubMed ID: 8933144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Collection and utilization of plasma in Austria: on the way to national self-sufficiency].
    Bergmann H; Lukas M; Prusa P
    Beitr Infusionsther Transfusionsmed; 1996; 33():103-10. PubMed ID: 8974681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Preparation-related effects on the coagulation activity of plasma].
    Schmitt H
    Beitr Infusionsther; 1989; 24():91-4. PubMed ID: 2481554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Blood coagulation and fibrinolysis in blood donors after plasmapheresis].
    Zukowska B; Kotschy M
    Pol Tyg Lek; 1992 Feb 3-10; 47(5-6):120-2. PubMed ID: 1437797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Donor vigilance data of a blood transfusion service: A multicenter analysis.
    Burkhardt T; Dimanski B; Karl R; Sievert U; Karl A; Hübler C; Tonn T; Sopvinik I; Ertl H; Moog R
    Transfus Apher Sci; 2015 Oct; 53(2):180-4. PubMed ID: 26074050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of plasma derivatives for clinical use.
    Tullis JL
    Vox Sang; 1972; 23(1):3-9. PubMed ID: 4117048
    [No Abstract]   [Full Text] [Related]  

  • 38. Editorial: Component transfusion therapy.
    Br Med J; 1974 Aug; 3(5930):544. PubMed ID: 4412928
    [No Abstract]   [Full Text] [Related]  

  • 39. Starting a plasmapheresis program with hollow-fiber filtration.
    van der Does JA; van Antwerpen CE
    Vox Sang; 1986; 51 Suppl 1():45-8. PubMed ID: 3090785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A method for preparing plasma factor 8 (antihemophilic globulin) concentrate.
    Simson LR; Oberman HA; Penner JA; Lien DM; Warner CL
    Am J Clin Pathol; 1966 Apr; 45(4):373-6. PubMed ID: 5910040
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.